{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:10:28Z","timestamp":1789038628524,"version":"build-2803163510"},"reference-count":30,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Anticancer therapies are associated with a prolongation of QT interval of electrocardiogram (ECG), increasing the risk of arrhythmias. To evaluate this risk in cardiovascular disease-free subjects with cancer, ECG recorded at baseline, months 3, 6 and 12 from 291 participants from the ONCOECHO database were analyzed. Methods: Both Fridericia (QTcF), considered as standard, and Bazett (QTcB) formulas were used to calculate corrected QT (QTc). Results: The study cohort consisted of 61.8% subjects with breast cancer, 26.5% with hematologic malignancies, 7.3% with colorectal cancer and 4.4% of patients with kidney cancer. At baseline, six patients had a QTcF \u2265 460 ms and one \u2265 500 ms. QTcF values differed significantly across time points (p = 0.0125), with a significant increase between baseline and month 6 (400.9 \u00b1 29 ms vs. 409.6 \u00b1 25 ms, p = 0.0075). Use of the Bazett formula resulted in 5.49 (95% CI 3.28\u20139.19) higher odds of identification of QTc \u2265 460 ms than with the Fridericia rule. A LASSO logistic regression model identified age, QTcF at baseline and month 3 to increase odds of QTcF \u2265 460 ms, whereas higher ejection fraction was associated with decreased odds. Conclusions: Analysis shows that cancer patients receiving cardiotoxic therapy are at relatively low risk of QTc prolongation, but choosing the appropriate QTc correction formula is essential.<\/jats:p>","DOI":"10.3390\/cancers18182936","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:27:21Z","timestamp":1789036041000},"page":"2936","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal Changes in QTc Interval in Cancer Patients After the Initiation of Systemic Therapy: Analysis of the ONCOECHO Study Cohort"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8548-9762","authenticated-orcid":false,"given":"Maciej","family":"Si\u0144ski","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hypertension and Vascular Diseases, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5219-7858","authenticated-orcid":false,"given":"M.","family":"Zaborska-Dworak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hypertension and Vascular Diseases, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0662-8678","authenticated-orcid":false,"given":"P.","family":"Sobieraj","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hypertension and Vascular Diseases, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lewandowski","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hypertension and Vascular Diseases, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5513-8371","authenticated-orcid":false,"given":"B.","family":"Zaborska","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Grochowski Hospital, Centre of Postgraduate Medical School, 04-073 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6907-2799","authenticated-orcid":false,"given":"K.","family":"Mizia-Stec","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, Medical University of Silesia, 40-635 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"G\u0105sior","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Health Sciences, Medical University of Silesia, 40-635 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5850-8187","authenticated-orcid":false,"given":"J. D.","family":"Kasprzak","sequence":"additional","affiliation":[{"name":"1st Department of Cardiology, Medical University of Lodz, 91-347 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8040-5109","authenticated-orcid":false,"given":"I.","family":"Kowalik","sequence":"additional","affiliation":[{"name":"Department of Coronary Artery Disease and Cardiac Rehabilitation, National Institute of Cardiology, 04-628 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Stachowiak","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"P.","family":"Go\u015bciniak","sequence":"additional","affiliation":[{"name":"Cardiometabolism and Cardio-Oncology Laboratory, Department of Endocrinology and Internal Medicine, Pomeranian Medical University, 71-252 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"ref_1","unstructured":"(2016). GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet, 388, 1459\u20131544."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40959-020-0057-2","article-title":"Hospitalized cancer patients with acquired long QT syndrome\u2014A matched case-control study","volume":"6","author":"Lin","year":"2020","journal-title":"Cardio-Oncology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: An International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1161\/CIR.0000000000000986","article-title":"Recognition, prevention, and management of arrhythmias and autonomic disorders in cardio-oncology: A scientific statement from the American Heart Association","volume":"144","author":"Fradley","year":"2021","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1042\/CS20200305","article-title":"Cardiotoxic effects of angiogenesis inhibitors","volume":"135","author":"Dobbin","year":"2021","journal-title":"Clin. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/14740338.7.2.181","article-title":"Sudden cardiac death secondary to antidepressant and antipsychotic drugs","volume":"7","author":"Sicouri","year":"2008","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"12329","DOI":"10.1073\/pnas.210244497","article-title":"A structural basis for drug-induced long QT syndrome","volume":"97","author":"Mitcheson","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","unstructured":"Food and Drug Administration, HHS, and International Conference on Harmonisation (2005). Guidance on E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability. Not. Fed. Regist., 70, 61134\u201361135."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/med.20019","article-title":"QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development","volume":"25","author":"Recanatini","year":"2005","journal-title":"Med. Res. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40959-024-00271-9","article-title":"Association between QT prolongation and cardiovascular mortality in cancer patients","volume":"10","author":"Chan","year":"2024","journal-title":"Cardio-Oncology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaccao.2021.01.002","article-title":"How to diagnose and manage QT prolongation in cancer patients","volume":"3","author":"Kim","year":"2021","journal-title":"JACC Cardio Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Reeves, D.J., Russell, M., and Rao, V.U. (2023). QTc prolongation risk among patients receiving oral targeted antineoplastic medications: A real-world community-based oncology analysis. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1098333"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e007724","DOI":"10.1161\/JAHA.117.007724","article-title":"Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: A systematic review","volume":"6","author":"Gilbert","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5603\/KP.a2016.0163","article-title":"Tissue Doppler echocardiography detects subclinical left ventricular dysfunction in patients undergoing chemotherapy for colon cancer: Insights from ONCOECHO multicentre study","volume":"75","author":"Kasprzak","year":"2017","journal-title":"Kardiol. Pol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.5114\/aoms.2020.100401","article-title":"Cardiovascular risk factors among cancer patients qualified for systemic treatment: Analysis of a cardiovascular disease-free cohort from the Polish multicentre study ONCOECHO","volume":"16","author":"Nowakowska","year":"2020","journal-title":"Arch. Med. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/01.CIR.88.2.782","article-title":"Diagnostic criteria for the long QT syndrome: An update","volume":"88","author":"Schwartz","year":"1993","journal-title":"Circulation"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/ijc.33119","article-title":"Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors","volume":"147","author":"Lin","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.15420\/aer.2023.04","article-title":"Ventricular arrhythmia in cancer patients: Mechanisms, treatment strategies and future avenues","volume":"12","author":"Agarwal","year":"2023","journal-title":"Arrhythm. Electrophysiol. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Agarwala, V., Ghosh, A., Guha, A., Parikh, P.M., and Dent, S. (2023). Editorial: Cancer treatment-related cardiovascular disease\u2014Real world data in cardio-oncology. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1277042"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Rowe, E.J., Shugg, T., Ly, R.C., Philips, S., Rosenman, M.B., Callaghan, J.T., Radovich, M., Overholser, B.R., Schneider, B.P., and Tisdale, J.E. (2022). Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancer. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.894623"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1001\/jamaoncol.2022.4194","article-title":"Association of QTc formula with the clinical management of patients with cancer","volume":"8","author":"Richardson","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00280-020-04153-6","article-title":"Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: An exposure\u2013Response analysis","volume":"87","author":"Fudio","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.15420\/ecr.2022.63","article-title":"The 2022 European Society of Cardiology cardio-oncology guidelines in focus","volume":"18","author":"Gent","year":"2023","journal-title":"Eur. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1200\/JCO.2003.99.104","article-title":"Baseline heart rate-corrected QT and eligibility for clinical trials in oncology","volume":"21","author":"Varterasian","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S1470-2045(22)00221-2","article-title":"The QT interval prolongation potential of anticancer and supportive drugs: A comprehensive overview","volume":"23","author":"Giraud","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s10637-012-9909-4","article-title":"Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials","volume":"31","author":"Borad","year":"2013","journal-title":"Investig. New Drugs"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e003264","DOI":"10.1161\/JAHA.116.003264","article-title":"Which QT correction formulae to use for QT monitoring?","volume":"5","author":"Vandenberk","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1093\/annonc\/mds130","article-title":"Electrocardiograms (ECGs) in phase I anticancer drug development: The MD Anderson Cancer Center experience with 8518 ECGs","volume":"23","author":"Naing","year":"2012","journal-title":"Ann. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2936\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:38:41Z","timestamp":1789036721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":30,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18182936"],"URL":"https:\/\/doi.org\/10.3390\/cancers18182936","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}